Atara Biotherapeutics Inc (ATRA)
0.5673
-0.04
(-6.02%)
USD |
NASDAQ |
May 08, 15:54
Atara Biotherapeutics Free Cash Flow: -194.20M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -194.20M |
| September 30, 2023 | -200.67M |
| June 30, 2023 | -214.23M |
| March 31, 2023 | -226.32M |
| December 31, 2022 | -274.62M |
| September 30, 2022 | -254.44M |
| June 30, 2022 | -252.09M |
| March 31, 2022 | -250.34M |
| December 31, 2021 | -231.10M |
| September 30, 2021 | -199.09M |
| June 30, 2021 | -189.72M |
| March 31, 2021 | -184.79M |
| December 31, 2020 | -185.27M |
| September 30, 2020 | -241.95M |
| June 30, 2020 | -242.12M |
| March 31, 2020 | -238.74M |
| December 31, 2019 | -241.36M |
| September 30, 2019 | -241.54M |
| June 30, 2019 | -240.51M |
| March 31, 2019 | -232.06M |
| December 31, 2018 | -215.70M |
| Date | Value |
|---|---|
| September 30, 2018 | -188.74M |
| June 30, 2018 | -162.57M |
| March 31, 2018 | -139.12M |
| December 31, 2017 | -107.73M |
| September 30, 2017 | -95.26M |
| June 30, 2017 | -84.80M |
| March 31, 2017 | -72.90M |
| December 31, 2016 | -63.04M |
| September 30, 2016 | -52.55M |
| June 30, 2016 | -49.50M |
| March 31, 2016 | -44.20M |
| December 31, 2015 | -37.45M |
| September 30, 2015 | -30.78M |
| June 30, 2015 | -21.96M |
| March 31, 2015 | -20.38M |
| December 31, 2014 | -16.67M |
| September 30, 2014 | -14.17M |
| June 30, 2014 | -11.76M |
| March 31, 2014 | -5.969M |
| December 31, 2013 | -5.969M |
Free Cash Flow Range, Past 5 Years
-274.62M
Minimum
Dec 2022
-184.79M
Maximum
Mar 2021
-226.48M
Average
-238.74M
Median
Mar 2020
Free Cash Flow Benchmarks
| NovaBay Pharmaceuticals Inc | -4.15M |
| Palatin Technologies Inc | -26.75M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -19.20M |
| Oragenics Inc | -7.291M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -50.41M |
| Cash from Investing (Quarterly) | 9.944M |
| Cash from Financing (Quarterly) | 1.512M |
| Free Cash Flow Per Share (Quarterly) | -0.4664 |
| Free Cash Flow to Equity (Quarterly) | -50.45M |
| Free Cash Flow to Firm (Quarterly) | -49.98M |
| Free Cash Flow Yield | -323.2% |